Company intelligence / Profile preview

Ocellaris Pharma, Inc.

Montréal, Quebec, Canadaannalsofoncology.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Ocellaris Pharma is developing OC‑001, a biologic targeting the TNF pathway for multiple oncology indications. The lead program is in Phase 1/2 clinical trials evaluating safety and pharmacokinetics in patients with locally advanced or metastatic cancers. The trial has expanded enrollment from 80 to 116 patients and remains actively recruiting as of mid‑2024. Early results have been positive regarding safety and proof-of-concept efficacy signals. The company was created as a special purpose vehicle to advance this single compound through proof-of-concept studies.

Therapeutic areas: Oncology
Modalities: Biological products (biologics)
Industry: Biotech

Drug pipeline

1 asset

OC-001

Unknown

Partnerships

TVM Capital Life Science Innovation II SCSp – sole financier/backer for development through proof-of-concept phase.

Beyond the preview

Go deeper on Ocellaris Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocellaris Pharma, Inc..

Explore the full profile